Search

Your search keyword '"J. R. Mel"' showing total 84 results

Search Constraints

Start Over You searched for: Author "J. R. Mel" Remove constraint Author: "J. R. Mel"
84 results on '"J. R. Mel"'

Search Results

1. Estimation of Canada's methane emissions: inverse modelling analysis using the Environment and Climate Change Canada (ECCC) measurement network

2. Implementing a dynamic representation of fire and harvest including subgrid-scale heterogeneity in the tile-based land surface model CLASSIC v1.45

3. Cold‐Season Methane Fluxes Simulated by GCP‐CH4 Models

4. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study

5. A map of global peatland extent created using machine learning (Peat-ML)

6. Global Carbon Budget 2021

7. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

8. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

9. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

10. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study

11. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

12. Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer

13. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

14. Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: A phase II trial

15. WETMETH 1.0: a new wetland methane model for implementation in Earth system models

16. Assessing the representation of the Australian carbon cycle in global vegetation models

17. Simulating shrubs and their energy and carbon dioxide fluxes in Canada's Low Arctic with the Canadian Land Surface Scheme Including Biogeochemical Cycles (CLASSIC)

18. CLASSIC v1.0: the open-source community successor to the Canadian Land Surface Scheme (CLASS) and the Canadian Terrestrial Ecosystem Model (CTEM) – Part 2: Global benchmarking

19. Linking global terrestrial CO2 fluxes and environmental drivers: inferences from the Orbiting Carbon Observatory 2 satellite and terrestrial biospheric models

20. Modelled land use and land cover change emissions – a spatio-temporal comparison of different approaches

21. Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

22. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02)

23. P2-255: Gemcitabine and oral vinorelbine in elderly patients with advanced non–small cell lung cancer (NSCLC). A phase II study conducted by the Galician Lung Cancer Group (GLCG)

24. Phase II study with conventional radiotherapy (RT) + cetuximab in patients with advanced larynx cancer who responded to induction chemotherapy (IC): An organ preservation TTCC study

25. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00)

26. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen

27. The Global Methane Budget 2000–2017

28. Quantitative assessment of fire and vegetation properties in simulations with fire-enabled vegetation models from the Fire Model Intercomparison Project

29. CLASSIC v1.0: the open-source community successor to the Canadian Land Surface Scheme (CLASS) and the Canadian Terrestrial Ecosystem Model (CTEM) – Part 1: Model framework and site-level performance

30. Global Carbon Budget 2019

31. Historical (1700–2012) global multi-model estimates of the fire emissions from the Fire Modeling Intercomparison Project (FireMIP)

32. Improving permafrost physics in the coupled Canadian Land Surface Scheme (v.3.6.2) and Canadian Terrestrial Ecosystem Model (v.2.1) (CLASS-CTEM)

33. Response of simulated burned area to historical changes in environmental and anthropogenic factors: a comparison of seven fire models

34. Sorafenib in Advanced Non-Small-Cell Lung Cancer: A Retrospective Analysis of Patients in Progression After Two or More Lines of Therapy

35. Sorafenib (SOR) in advanced non-small cell lung cancer (NSCLC): A phase II study of patient progress after several lines of treatment

36. AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: OS analysis

37. Value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab (B) in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy (AVALUZ trial)

38. 9088 POSTER Erlotinib as Frontline Treatment for Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and Non-Squamous Histology – Results of a Galician Lung Cancer Group (GGCP044/09 Study) Grupo Galego De Cancro De Pulmon (GGCP)

39. Clinical value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy

40. First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis

41. Maintenance treatment with cetuximab in a series of patients treated with standard chemotherapy and cetuximab in metastatic colorectal cancer

42. An improved parameterization of leaf area index (LAI) seasonality in the Canadian Land Surface Scheme (CLASS) and Canadian Terrestrial Ecosystem Model (CTEM) modelling framework

43. Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC)

44. Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer

45. Neoadyuvant therapy with dose-dense (DD) docetaxel (T) and doxorubicin/cyclophosphamide (AC) in locally advanced breast cancer (LABC)

46. Docetaxel (D) and cisplatin (C) induction chemotherapy followed by bi-weekly D with concurrent thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study

47. Phase II study of biweekly docetaxel and cisplatin combination chemotherapy in first-line advanced gastric cancer

48. Oral vinorelbine (NVBO) and gemcitabine (GEM) in elderly patients with advanced non-small-cell lung cancer (NSCLC): A phase II study conducted by the Galician Lung Cancer Group (GLCG)

49. 6615 POSTER Biweekly paclitaxel as second-line treatment in advanced non-small-cell-lung-cancer (NSCLC). A phase II study of the Galician Lung Cancer Group

50. P2-317: Biweekly paclitaxel as second-line treatment in advanced non-small-cell-lung-cancer (NSCLC). A phase II study of the Lung Cancer Galician Group

Catalog

Books, media, physical & digital resources